Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer
Authors:
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 156 (3) , 530-534
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcomeEuropean Journal of Cancer, 2016
- Primary chemotherapy versus primary surgery for ovarian cancer – Authors' replyThe Lancet, 2015
- Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian CancerJournal of Clinical Oncology, 2015
- Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?Gynecologic Oncology, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Practice patterns of intraperitoneal chemotherapy in women with ovarian cancerGynecologic Oncology, 2009
- Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009Gynecologic Oncology, 2009
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Intraperitoneal chemotherapy in the management of malignant diseaseExpert Review of Anticancer Therapy, 2001
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996